Previous 10 | Next 10 |
Lantern Pharma Inc. (LTRN) Q3 2020 Results Conference Call October 29, 2020 04:00 PM ET Company Participants Marek Ciszewski - Director, IR Panna Sharma - President and CEO David Margrave - CFO Conference Call Participants Kyle Bauser - Colliers John Vandermosten - Zacks Small Cap Presentatio...
Lantern Pharma (LTRN): Q3 GAAP EPS of $0.27 beats by $0.56.Cash, cash equivalents of $20.8M.Press Release. For further details see: Lantern Pharma EPS beats by $0.56
Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress - Surpassed One Billion Curated Data Points Powering Company's Proprietary A.I. P...
Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results Conference Call on October 29, 2020 at 4:00 p.m. ET PR Newswire DALLAS, Oct. 22, 2020 DALLAS , Oct. 22, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage ...
Gainers: Organovo Holdings (ONVO) +12%, Lantern Pharma (LTRN) +11%, Cancer Genetics (CGIX) +10%, American Well (AMWL) +10%, Immuron (IMRN) +9%.Losers: Avenue Therapeutics ATXI -57%, Zynex ZYXI -27%, Fortress Biotech FBIO -22%, &...
Lantern Pharma (LTRN) has announced the advancement of its collaboration with Georgetown University for LP-184, a small molecule drug candidate currently in preclinical development for certain genomically defined solid tumors.The first phase of the collaboration was a proof of concept st...
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent PR Newswire DALLAS, Oct. 5, 2020 DALLAS , Oct. 5, 2020 /PRNewswire/ -- Lantern Pharma (NA...
Lantern Pharma (LTRN) will collaborate with Philadelphia's Fox Chase Cancer Center on the development of LP-184 in pancreatic cancer. Specifically, the partnership will focus on advancing the targeted use of LP-184, a small molecule alkylating agent, in molecularly defined subtypes of pancrea...
Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer PR Newswire DALLAS, Sept. 22, 2020 DALLAS , Sept. 22, 2020 /PRNewswire/ -- Lantern Pharma (Nasd...
Gainers: Novus Therapeutics (NASDAQ: NVUS ) +162% . More news on: Novus Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...